New to peptides? Start with the foundations ->
The dad-test answer
Tesamorelin (Egrifta) is FDA-approved for HIV-related lipodystrophy with strong trial evidence for visceral-fat reduction. CJC-1295 is a research peptide used in the biohacker GH-axis stack alongside ipamorelin. Tesamorelin is the regulatory-grade molecule with a real prescribing path; CJC-1295 is the operator stack that gets you closer to natural GH pulsing.
Who wins for what
| Use case | Who wins, and why |
|---|---|
| visceral adipose tissue (VAT) reduction |
tesamorelin Phase 3 trials in HIV-lipodystrophy patients showed about 15% VAT reduction at 6 months; off-label evidence in non-HIV adults is reasonable. |
| GH-axis recovery / sleep / general anti-aging |
cjc-1295 + ipamorelin stack Pulsatile GH release closer to physiologic pattern; standard biohacker protocol. |
| FDA-approved, insurance-covered path |
tesamorelin Egrifta (and Egrifta SV) are FDA-approved for lipodystrophy; CJC-1295 is research-use only. |
| cost |
cjc-1295 (compounded) Tesamorelin retail can run $4-5K/month without insurance; compounded CJC-1295 + ipamorelin is a fraction of that. |
What the head-to-head data shows
Tesamorelin is a synthetic GHRH analog FDA-approved as Egrifta in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The pivotal trials (Falutz et al., NEJM 2007 and follow-up Phase 3 work) showed about 15% reduction in visceral adipose tissue at 26 weeks via daily subQ injection. CJC-1295 is a longer-acting GHRH analog characterized in Teichman et al. 2006; it is research-use-only without FDA approval. The biohacker GH-axis stack pairs CJC-1295 (no DAC) with ipamorelin to produce pulsatile GH release - Raun et al. 1998 covers ipamorelin's selective ghrelin-receptor activity. Both peptides target the same physiological end (raising endogenous GH and IGF-1), but tesamorelin is the one with full FDA approval and Phase 3 trial data behind a specific clinical use.
Our honest call
If a reader has a clinical indication for VAT reduction - particularly HIV-related lipodystrophy, but also adults whose visceral fat hasn't responded to GLP-1 therapy or lifestyle work - tesamorelin is the molecule with real FDA-approved evidence. The cost is the friction. For general GH-axis support (sleep, recovery, body recomp), the CJC-1295 + ipamorelin stack is the standard biohacker protocol and produces pulsatile GH release closer to physiologic pattern - but the evidence tier drops to research-grade and biohacker-anecdotal. Read the tesamorelin VAT protocol for the regulatory path or the CJC-1295 + ipamorelin protocol for the operator stack.
Sources and citations
- Falutz et al., Tesamorelin Phase 3 in HIV lipodystrophy, NEJM 2007 (PMID 18075072)
- FDA Egrifta prescribing label (approved Nov 2010)
- Teichman et al., CJC-1295 in healthy adults, J Clin Endocrinol Metab 2006 (PMID 16352683)
- Raun et al., Ipamorelin GH-releasing peptide, Eur J Endocrinol 1998 (PMID 9849822)
- Theratechnologies Egrifta SV prescribing information
Where to go next
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine. None of this replaces a doctor. Peptides are gray-market in the US for most uses. Talk to a real prescriber before you change anything.